GSA Capital Partners LLP Lowers Stock Position in Omnicell, Inc. (NASDAQ:OMCL)

GSA Capital Partners LLP cut its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 62.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,966 shares of the company’s stock after selling 8,139 shares during the quarter. GSA Capital Partners LLP’s holdings in Omnicell were worth $217,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in OMCL. Nisa Investment Advisors LLC lifted its position in shares of Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the period. GAMMA Investing LLC raised its holdings in Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the last quarter. CWM LLC boosted its position in Omnicell by 68.2% during the second quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares in the last quarter. 1620 Investment Advisors Inc. grew its holdings in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in shares of Omnicell in the second quarter valued at $104,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the stock. Benchmark restated a “buy” rating and set a $48.00 target price on shares of Omnicell in a report on Wednesday, October 9th. Bank of America reissued a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays lifted their price objective on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Craig Hallum increased their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $52.00.

Omnicell Trading Up 3.6 %

OMCL stock opened at $45.69 on Monday. The firm has a 50 day simple moving average of $44.27 and a 200-day simple moving average of $37.41. The company has a market capitalization of $2.12 billion, a P/E ratio of -117.15, a PEG ratio of 37.10 and a beta of 0.81. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $55.74.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.